Agile And Differentiated, AlphaMab Riding High In China Biotech Boom
This article was originally published in PharmAsia News
Executive Summary
AlphaMab is attracting attention as the Suzhou-based biotech has filed China's first PD-L1 antibody, giving it a lead over larger and multinational competitors. The venture’s winning strategy lies in staying ahead of the curve, CEO Xu Ting told PharmAsia News in an exclusive interview.